Drug Profile

Lutetium-177 oxodotreotide - Curium Pharma

Alternative Names: Lu-177 DOTATATE - Curium Pharma; Lutetium Lu 177 Dotatate injection - Curium Pharma

Latest Information Update: 25 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Curium Pharma
Class Antineoplastics; Drug conjugates; Peptides; Radioisotopes; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preregistration Neuroendocrine tumours

Most Recent Events

18 Jun 2026 Curium pharma prevails the patent dispute by Advanced Accelerator Applications against Curium’s Lutetium Lu 177 dotatate product
18 Jun 2026 Curium Pharma announces intention launch Lutetium-177 oxodotreotide for Neuroendocrine tumours in the US
09 Jul 2024 Preclinical trials in Neuroendocrine tumours in France (Parenteral) before July 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com